When KCL-HO-1i was combined with either 5-FU or gemcitabine there was a synergistic enhancement in the prevalence of CD8+ T-cells in the TME (Figure 4D and S5C), which was associated with tumor control (Figure 4B). The gene discussed is CD8A; the disease is neoplasm.